北大医药(000788) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥512,301,458.44, representing a 41.20% increase compared to ¥362,812,695.12 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥22,998,217.21, a significant increase of 124.20% from ¥10,257,967.08 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥22,752,671.65, up 123.97% from ¥10,158,581.00 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.0386, which is a 124.42% increase compared to ¥0.0172 in the same period last year[8]. - The total profit for Q1 2021 was approximately ¥28.48 million, up 122.08% from ¥12.82 million in Q1 2020[15]. - The total comprehensive income for Q1 2021 was CNY 22,997,368.17, compared to CNY 10,370,528.91 in Q1 2020, indicating a significant increase[48]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,319,603,895.99, reflecting a 0.58% increase from ¥2,306,200,821.07 at the end of the previous year[8]. - The total liabilities as of Q1 2021 amounted to CNY 250,631,016.71, a decrease of 4.5% from CNY 262,866,367.89 in the previous year[47]. - Total assets increased to CNY 2,319,603,895.99 as of March 31, 2021, compared to CNY 2,306,200,821.07 at the end of 2020, reflecting a growth of approximately 0.58%[38]. - Total liabilities decreased to CNY 1,005,133,576.19 from CNY 1,014,727,869.44, reflecting a reduction of about 0.70%[40]. - Current assets totaled CNY 2,029,740,215.61, slightly up from CNY 2,020,161,337.01, indicating a marginal increase of about 0.09%[38]. Cash Flow - The net cash flow from operating activities for Q1 2021 was -¥15,287,950.66, which is an improvement of 45.25% compared to -¥27,921,120.06 in the same period last year[8]. - Operating cash inflow for the current period reached ¥559,487,360.65, an increase of 25.1% compared to ¥447,205,856.53 in the previous period[54]. - Cash outflow for purchasing goods and services was ¥304,272,675.04, up 36% from ¥223,936,958.77 in the previous period[54]. - Cash and cash equivalents at the end of the period totaled ¥351,310,626.07, down from ¥524,714,007.50 in the previous period[55]. - The cash flow from operating activities showed a net increase of ¥5,738,006.21, a significant recovery from -¥26,551,936.57 in the previous period[56]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,505[11]. - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 28.58% of the shares, amounting to 170,356,260 shares, with 9,500,000 shares frozen[11]. - The controlling shareholder, Chengsheng Group, holds 170,356,260 shares, accounting for 28.58% of the total share capital, with 86,000,000 shares (14.43%) used for margin financing with Zhongtai Securities[23]. - The second largest shareholder, Peking University Medical, holds 70,328,949 shares, representing 11.80% of the total share capital, with 70,000,000 shares (11.75%) used for margin financing with Huajin Securities[24]. Contracts and Agreements - The company has entered into a joint research agreement for the development of the innovative drug SKL-PSL, with shared responsibilities among partners including clinical trials and regulatory submissions[16]. - The company has signed a long-term service contract with Peking University International Hospital, with an estimated total contract value of ¥1 billion per year for three years[19]. - The company has established an industrial merger fund with a target capital contribution of between ¥500 million and ¥700 million, with the company planning to invest ¥3 million[18]. Other Financial Metrics - The weighted average return on equity for Q1 2021 was 1.76%, an increase of 0.94% from 0.82% in the previous year[8]. - Research and development expenses for Q1 2021 were CNY 1,310,327.26, down 28.8% from CNY 1,842,713.96 in Q1 2020[47]. - The company reported a financial expense of CNY 2,706,487.29, which includes interest expenses of CNY 4,320,493.09, a decrease from CNY 5,965,761.47 in the previous year[47]. - The company has not engaged in any securities or derivative investments during the reporting period[27][28]. - There are no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[26].